J. Grace van der Gugten
Papers
2
Total Citations
53
H-Index
2
About
J. Grace van der Gugten is a leading clinical mass spectrometrist whose research focuses on developing innovative mass spectrometry-based assays for clinical diagnostics and therapeutic drug monitoring. Her major contributions include the creation of an immuno-MALDI (iMALDI) assay for angiotensin I, enabling more accurate diagnosis of secondary hypertension by measuring plasma renin activity—a method that overcomes the limitations of traditional radioimmunoassays. This seminal work has garnered 40 citations, underscoring its impact on clinical chemistry. She also pioneered an automated mass spectrometric blood test for therapeutic drug monitoring of infliximab, a monoclonal antibody used to treat chronic immune-mediated diseases like Crohn’s disease and rheumatoid arthritis. This 2019 study, with 13 citations, offers a faster, more specific alternative to conventional immunoassays, improving patient management by enabling precise dose adjustments. Van der Gugten’s work bridges analytical chemistry and clinical medicine, advancing personalized treatment through robust, high-throughput technologies. Her achievements highlight her role as a key innovator in translating mass spectrometry from research labs into routine clinical practice, benefiting both clinicians and patients.
Research Focus
Key Achievements
Top Papers
- 1
- 2